Shaanxi Provincial People's Hospital
63
12
12
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
3.2%
2 terminated/withdrawn out of 63 trials
88.2%
+1.7% vs industry average
22%
14 trials in Phase 3/4
7%
1 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (63)
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis
Role: collaborator
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
Role: collaborator
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
Role: collaborator
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Role: collaborator
Optimizing Early Nutrition Support in Severe Stroke-2
Role: collaborator
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Role: collaborator
68Ga-PSMA PET in the Renal Cell Carcinoma
Role: collaborator
Plasma Exosome RNA to Diagnose Prostate Cancer
Role: collaborator
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
Role: collaborator
Coronary Arterial Microcirculation and Metabolism
Role: lead
A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
Role: collaborator
Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial
Role: collaborator
Clinical Characteristics and Prognosis of Aortic Dissection in China (CLASSIC)
Role: collaborator
Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）
Role: collaborator
Risk Factors for Chronic Prostatitis Patients in Northwest China
Role: lead
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
Role: collaborator
Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)
Role: collaborator
Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias
Role: collaborator
Acute Cerebrovascular Events in Patients Undergoing Catheter Ablation
Role: collaborator